Teunissen C E, Petzold A, Bennett J L, Berven F S, Brundin L, Comabella M, Franciotta D, Frederiksen J L, Fleming J O, Furlan R, Hintzen R Q, Hughes S G, Johnson M H, Krasulova E, Kuhle J, Magnone M C, Rajda C, Rejdak K, Schmidt H K, van Pesch V, Waubant E, Wolf C, Giovannoni G, Hemmer B, Tumani H, Deisenhammer F
Department of Molecular Cell Biology and Immunology, VU University Medical Center, Amsterdam, The Netherlands.
Neurology. 2009 Dec 1;73(22):1914-22. doi: 10.1212/WNL.0b013e3181c47cc2.
There is a long history of research into body fluid biomarkers in neurodegenerative and neuroinflammatory diseases. However, only a few biomarkers in CSF are being used in clinical practice. One of the most critical factors in CSF biomarker research is the inadequate powering of studies because of the lack of sufficient samples that can be obtained in single-center studies. Therefore, collaboration between investigators is needed to establish large biobanks of well-defined samples. Standardized protocols for biobanking are a prerequisite to ensure that the statistical power gained by increasing the numbers of CSF samples is not compromised by preanalytical factors. Here, a consensus report on recommendations for CSF collection and biobanking is presented, formed by the BioMS-eu network for CSF biomarker research in multiple sclerosis. We focus on CSF collection procedures, preanalytical factors, and high-quality clinical and paraclinical information. The biobanking protocols are applicable for CSF biobanks for research targeting any neurologic disease.
对神经退行性疾病和神经炎症性疾病中的体液生物标志物进行研究已有很长的历史。然而,目前只有少数脑脊液生物标志物应用于临床实践。脑脊液生物标志物研究中最关键的因素之一是研究的样本量不足,因为单中心研究难以获得足够的样本。因此,研究人员之间需要开展合作,以建立大型的、定义明确的样本生物样本库。生物样本库的标准化方案是确保增加脑脊液样本数量所带来的统计效力不受分析前因素影响的前提条件。在此,由BioMS-eu网络针对多发性硬化症脑脊液生物标志物研究撰写的一份关于脑脊液采集和生物样本库建议的共识报告发布。我们重点关注脑脊液采集程序、分析前因素以及高质量的临床和辅助临床信息。这些生物样本库方案适用于针对任何神经系统疾病研究的脑脊液生物样本库。